Skip to main content

Table 2 TNF-α and IL-10 production in unchallenged PBMCs incubated with oligosaccharide fractions

From: In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation

  TNF- α (pg/ml)    IL-10 (pg/ml)   
Incubation Point estimate Lower bound Upper bound Point estimate Lower bound Upper bound
Blank controls 12.6 9.8 15.7 187.2 156.2 222.5
GOS 0.5% 19.7 * 16.5 23.3 183.1 152.8 217.7
GOS 1.0% 24.9 * 21.1 29.3 184.2 153.5 219.2
GOS 2.0% 35.5 * # 30.2 41.6 179.8 149.6 214.2
GOS/FOS 0.5% 30.2 * 25.7 35.4 185.5 154.8 221.4
GOS/FOS 1.0% 63.4 * # 54.1 74.2 190.2 160.0 225.7
GOS/FOS 2.0% 127.5 * # 108.6 149.5 186.0 154.5 221.4
GOS/FOS/AOS 0.5% 73.6 * 62.9 86.4 205.2 173.8 242.5
GOS/FOS/AOS 1.0% 133.5 * # 113.7 156.6 214.2 181.6 252.4
GOS/FOS/AOS 2.0% 61.4 * # 52.4 72.2 186.8 157.3 221.0
  1. Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible Intervals for unchallenged PBMCs incubated with oligosaccharide fractions (including blank controls). Significant differences between oligosaccharide fractions and blank controls are marked with an asterisk (*) Significant dose-dependent differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a hash (#).